February 11, 2026
________________________________________________________________________________________________
Kindling Bio recently took part in two leading European events bringing together the paediatric oncology community and Europe’s cancer innovation ecosystem.
Accelerate Multi-Stakeholder Platform
On 6th February in Brussels, Kindling Bio CEO and co-founder Aleck Jones was invited to speak at the Accelerate Multi-Stakeholder Platform, sharing the company’s vision for a fundamentally different child-first cancer gene therapy platform and engaging with stakeholders from across the paediatric oncology ecosystem.
The discussions reinforced that the international regulatory environment is becoming increasingly supportive of paediatric-led innovation as Kindling Bio builds a long-term path toward first-in-child clinical impact. In Europe, the EU Biotech Act is helping shape a clearer framework for advanced therapies, while in the US, initiatives such as the Give Kids a Chance Act and Priority Review Voucher reauthorisation continue to strengthen incentives for paediatric development.
The event also gave us the chance to connect with patient advocates and organisations worldwide, alongside researchers, clinicians and industry leaders. Those conversations are helping us build the relationships we need as we move toward the clinic and keep children and families at the centre of what we build.
Kindling Bio is grateful for the invitation and the community behind the platform, and looks forward to returning next year.
More information: Accelerate Multi-Stakeholder Platform
Paris-Saclay Cancer Cluster Innovation Forum (Paris)
Co-founders Aleck Jones and Jeff Drew also attended the Paris-Saclay Cancer Cluster (PSCC) Innovation Forum, joining a broad community of researchers, clinicians, startups, industry and investors working to accelerate progress in cancer innovation.
For Kindling Bio, the day was an important opportunity to strengthen relationships across the PSCC ecosystem, including the mentoring and support that we continue to benefit from through the PSCC BOOST programme, following our 1st Prize win at Hack4Hope in December 2025.
The forum also provided a valuable opportunity to begin new discussions with potential partners as we plan ahead for the expertise and relationships needed to support manufacturing at scale, navigate the regulatory landscape, and move efficiently toward the clinic. We also welcomed the chance to build new connections with investors aligned with our child-first mission.
More information: Paris-Saclay Cancer Cluster
Looking Ahead
Both events reinforced that meaningful progress in paediatric oncology depends on building early relationships across research, clinical care, regulation and manufacturing, grounded in close partnership with the advocates and organisations working alongside children and families every day.
Kindling Bio is continuing to build from our base at the London Cancer Hub, advancing our child-first cancer gene therapy platform while strengthening the relationships needed to move efficiently toward the clinic.
About Kindling Bio
Kindling Bio is a biotechnology company developing paediatric-led, next-generation cancer gene therapies designed to reprogramme tumour biology and harness children’s immune responses to fight a wide range of tumours. The company is based at the London Cancer Hub.
